Remove 2022 Remove Marketing Remove Packaging Remove Regulations
article thumbnail

Zebrafish Value Proposition for Cosmetic Testing

biobide

Background on the Cosmetics industry In 2022, the value of the global cosmetics market was estimated to be worth USD 262.21 Additional contributing factors include an increased awareness of fashion trends, innovations in the areas of hair coloring and skincare product formulations, and developments in the area of packaging.

article thumbnail

Article EMA Thank You What we expect European regulators to do in August and September 2024

Agency IQ

What we expect European regulators to do in August and September 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Regulatory Developments in Ophthalmology: Applying New FDA Guidance, Part One

The Premier Consulting Blog

The global ophthalmic drugs market size was valued at $33.81 billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. The FDA has determined that ophthalmic dispensers are now regulated as devices, and the drug and device together are regulated as a combination product.

FDA 52
article thumbnail

Commercial interests contribute to drug use and addiction

National Institute on Drug Abuse: Nora's Blog

Great progress has been made in reducing smoking in the United States, which has led to major improvements in health, but the rapidly growing vaping industry, if not properly regulated, could jeopardize this. Adolescents exposed to cannabis marketing have greater odds of using the drug.

Drugs 105
article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. According to EFPIA, RDP protects an innovator’s investment by granting a limited period of exclusivity on the data it generated, starting from marketing authorisation 4.

article thumbnail

FDA Alerts the Public to Potentially Contaminated Products from Family Dollar Stores in Six States

The Pharma Data

Food and Drug Administration is alerting the public that several categories of FDA-regulated products purchased from Jan. This alert covers FDA-regulated products purchased from Family Dollar stores in those six states from Jan. Recalls, Market Withdrawals & Safety Alerts Report a Problem to the FDA. ###. Today, the U.S.

article thumbnail

Highs and lows of drug repurposing 

Drug Discovery World

A report by the medical charity LifeArc 1 puts the timeframe for a therapy brought to market through repurposing methods at anywhere from one to three years. This is a stark contrast to the often decade-long projects that pharmaceutical companies undertake to bring a drug to market. Volume 23 – Issue 4, Fall 2022. References .